The Association for the Accreditation of Human Research Protection Programs announced that it has accredited two more organizations: Boise VA Medical Center in Boise, Idaho, and VA Puget Sound Health Care System in Seattle, Wash.
All told, 243 organizations have now earned accreditation, including institutions in 46 states, the District of Columbia, Puerto Rico, Canada, China, India, Korea, and Singapore.
The latest accreditations come as AAHRPP marks 10 years since the issuance of the first accreditation standards in 2002. "Our progress has been remarkable," said Marjorie A. Speers, Ph.D., AAHRPP president and CEO. "A decade ago, accreditation was virtually unheard of. Today, it is synonymous with high-quality research and ethical treatment of research participants."
Speers gives much of the credit for AAHRPP's success to the research enterprise. "Accreditation has taken hold because the research community genuinely cares about protecting participants," she said. "Despite the challenges of the past decade, the research community has stood firm and embraced the rigors of accreditation."
Accreditation is available to US and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. The list of accredited organizations includes community and teaching hospitals; VA facilities, universities; institutional review boards; research institutes and contract research organizations.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.